REPLIGEN CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
REPLIGEN CORP (RGEN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $26.32 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-07-29
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $26.32M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $19.95M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $34.88M.
- 2022-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $75.63M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2026-06-30 | $26.32M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $19.95M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $34.88M 10-Q · filed 2026-07-29 |
| 2022-09-30 | $75.63M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $67.38M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $82.99M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $131.71M 10-Q · filed 2022-11-01 |
| 2021-09-30 | $154.15M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $101.36M 10-Q · filed 2021-07-27 |
| 2021-03-31 | $101.55M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $102.96M 10-K · filed 2022-02-17 |
| 2020-09-30 | $77.10M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $65.24M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $58.26M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $59.07M 10-K · filed 2020-02-26 |
| 2019-09-30 | $44.40M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $54.97M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $31.47M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $25.27M 10-K · filed 2019-03-01 |
| 2018-09-30 | $29.42M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $21.52M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $12.18M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $11.56M 10-K · filed 2018-02-22 |
| 2017-09-30 | $13.21M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $17.14M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $12.71M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $12.73M 10-K · filed 2017-02-23 |
| 2016-09-30 | $22.17M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $21.15M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $20.68M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $22.65M 10-K · filed 2016-02-25 |
| 2015-09-30 | $22.29M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $39.98M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $27.10M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $14.26M 10-K · filed 2015-03-17 |
| 2014-09-30 | $15.60M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $20.48M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $12.26M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $13.81M 10-K · filed 2014-03-14 |
| 2013-09-30 | $10.39M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $6.69M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $5.62M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $4.85M 10-K · filed 2013-03-15 |
| 2012-09-30 | $4.96M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $1.71M 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |